Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 13/20 | 0.41 |
| ▸ | SRC | P12931 | 7/20 | 0.40 |
| ▸ | ZAP70 | P43403 | 6/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | LYN | P07948 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899942 | 0.84 | LYN (0.49) | SYKSRCZAP70CDK2RAB9A | |
| SCHEMBL27682364 | 0.81 | SYK (0.38) | SYKSRCZAP70CDK2RAB9A | |
| SCHEMBL27682393 | 0.81 | RAB9A (0.40) | SYKSRCZAP70CDK2RAB9A | |
| SCHEMBL4896690 | 0.81 | SYK (0.49) | SYKSRCZAP70CDK2RAB9A | |
| SCHEMBL4901358 | 0.81 | SLC2A1 (0.49) | SYKSRCZAP70CDK2RAB9A | |
| SCHEMBL4899975 | 0.81 | RAB9A (0.40) | SYKSRCZAP70CDK2RAB9A | |
| Hydrochloric Acid SCHEMBL4895812 | 0.81 | SYK (0.37) | SYKSRCZAP70CDK2RAB9A | |
| SCHEMBL4899309 | 0.81 | SYK (0.40) | SYKSRCZAP70CDK2RAB9A | |
| SCHEMBL4899241 | 0.81 | CYP1A1 (0.48) | SYKSRCZAP70CDK2RAB9A | |
| SCHEMBL4902132 | 0.81 | SYK (0.40) | SYKSRCZAP70CDK2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108600-A1 | Polycyclic Pyridines as Potassium Ion Channel Modulators | ICAGEN, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1737852-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100349-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108600-A1 | Polycyclic Pyridines as Potassium Ion Channel Modulators | KCNJ2, KCNH2, KCNQ1 | SYK 4140/4885SRC 4155/4885ZAP70 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.